Skip to content
drillr.ai
Sign up

ALZN

Alzamend Neuro, Inc.

NASDAQ · Healthcare · Biotechnology · US

$1.72
+0.88%
Ask drillr
Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
Market Cap
$8.28M
RSI (14)
67.7
MomentumView details →
1D Return
+0.88%
YTD Return
−5.49%
SummaryUpdated Apr 1, 2026

Alzamend Neuro, Inc. (NASDAQ:ALZN) is an early-stage biopharmaceutical company founded in 2016 and headquartered in Atlanta, Georgia. The company went public in June 2021 and focuses on developing therapeutic treatments for neurodegenerative diseases and psychiatric disorders, with particular emphasis on Alzheimer's disease. As a clinical-stage biotech firm, Alzamend operates in the highly regulated pharmaceutical development space, where companies typically spend years and significant capital conducting clinical trials before potentially bringing products to market.

Ask drillr about Alzamend Neuro, Inc. →

Similar companies

Soligenix, Inc.SNGXSkye Bioscience, Inc.SKYEExicure, Inc.XCURTraws Pharma, Inc.TRAWEnsysce Biosciences, Inc.ENSCCuprina Holdings (Cayman) Limited Class A Ordinary SharesCUPR
Latest newsMore news →
Alzamend Neuro announced the initial closing of a securities purchase agreement with Ault Lending, receiving $7.5 million in gross proceeds from the sale of Series D Convertible Preferred Stock, with up to $17.5 million in additional funding available through subsequent tranches.31d ago